The nocebo effect challenges the non-medical infliximab switch in practice
Open Access
- 24 January 2018
- journal article
- research article
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 74 (5) , 655-661
Abstract
Background In clinical practice, non-medical switching of biological medication may provoke nocebo effects due to unexplained deterioration of therapeutic benefits. Indication extrapolation, idiosyncratic reactions, and interchangeability remain challenged in clinical practice after biosimilar approval by the European Medicines Agency. The principle of “first do no harm” may be challenged in a patient when switching from originator to biosimilar biological. Aim To describe the 1-year results of a pragmatic study on infliximab biosimilar implementation in immune-mediated inflammatory disease patients on the basis of shared decision-making under effectiveness and safety monitoring. Methods Inflammatory bowel disease and rheumatology patients on infliximab originator were converted to infliximab biosimilar after providing informed consent. Nocebo response patients were monitored after switch back to originator. Linear mixed models were used to analyze continuous endpoints on effectiveness and laboratory outcomes to determine significance (P ≤ 0.05) of change over time after switching. Results After inviting 146 patients, a group of 125 patients enrolled in the project over time, respectively, 73 Crohn’s disease, 28 ulcerative colitis, nine rheumatoid arthritis, ten psoriatic arthritis, and five ankylosing spondylitis patients. No statistically significant changes in effectiveness and safety were observed in any of the indications after a median of 4 infusions in 9 months of study. An overall nocebo response of 12.8% was found among the patients during a minimal observation period of 6 months after the transition to biosimilar infliximab. The overall nocebo response rate did not differ between the studied indications. Conclusions In inflammatory bowel disease and rheumatological patients, similar effectiveness and safety were demonstrated on the transition into infliximab biosimilar. In our series, patient empowerment and registration of treatment outcomes delineated biosimilar transition, an approach that hypothetically could reduce nocebo response rates which are relevant to account for regarding biosimilar implementation.Keywords
This publication has 15 references indexed in Scilit:
- The nocebo effect of drugsPharmacology Research & Perspectives, 2016
- Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational dataExpert Opinion on Biological Therapy, 2015
- SGLT2-remmers en diabetische ketoacidosesNederlands Tijdschrift voor Diabetologie, 2015
- A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS studyAnnals of the Rheumatic Diseases, 2013
- Ten Years of Infliximab for Crohn’s DiseaseInflammatory Bowel Diseases, 2013
- Therapeutic Drug Monitoring of Tumor Necrosis Factor Antagonists in Inflammatory Bowel DiseaseClinical Gastroenterology and Hepatology, 2012
- Detection of infliximab levels and anti‐infliximab antibodies: a comparison of three different assaysAlimentary Pharmacology & Therapeutics, 2012
- Analyzing Longitudinal Data With the Linear Mixed Models Procedure in SPSSEvaluation & the Health Professions, 2009
- Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritisArthritis & Rheumatism, 2006
- THE BATH ANKYLOSING SPONDYLITIS PATIENT GLOBAL SCORE (BAS-G)Rheumatology, 1996